Xinhua Pharmaceutical receives approval for pentazocine injection

Shandong Xinhua Pharmaceutical (SZSE:000756) announced that it has received approval from the National Medical Products Administration for its Pentazocine Injection. Classified as a chemical drug, the injection is a prescription medication indicated for pain management. The related Pentazocine raw material is self-produced by Xinhua Pharmaceutical and already obtained approval in November 2024. Data shows China's public medical institutions had nearly $1.27 million (RMB 9.15 million) in sales of the drug in 2023. The company believes the approval enhances its product portfolio and strengthens its core competitiveness. However, Xinhua Pharmaceutical cautioned investors that the pharmaceutical business is subject to policy changes and market fluctuations.